ProMIS Neurosciences Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

PMN$4.05-2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets


· · September 30, · · December 31, ·
· 2024 · 2023 ·
Assets
Current assets:
Cash	$21,536,898	$12,598,146
Short-term investments	32,358	32,358
Prepaid expenses and other current assets	2,941,279	988,641
Total current assets	24,510,535	13,619,145
Total assets	$24,510,535	$13,619,145
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable	$1,575,235	$7,843,136
Accrued liabilities	1,059,852	1,506,526
Total current liabilities	2,635,087	9,349,662
Share-based compensation liability	340,090	422,002
Warrant liability	14,262,138	94,185
Total liabilities	17,237,315	9,865,849

Commitments and contingencies
Shareholders' equity:
Series 2 Convertible Preferred Shares, no par value, unlimited shares authorized, 0 and 1,166,667 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	—	—
Common shares, no par value, unlimited shares authorized, 32,689,190 and 18,885,254 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	—	—
Additional paid-in capital	98,093,270	97,590,426
Accumulated other comprehensive loss	(371,184)	(371,184)
Accumulated deficit	(90,448,866)	(93,465,946)
Total shareholders' equity	7,273,220	3,753,296
Total liabilities and shareholders' equity	$24,510,535	$13,619,145

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.